It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X
1
represents CH or N; any one of X
2
, X
3
and X
4
represents N, and the others represent CH; any one or two of Y
1
, Y
2
, Y
3
and Y
4
represent C—R
4
, and the others are the same or different and represent CH or N; R
1
represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S and O; R
2
represents an alkyl group having 1 to 6 carbon atoms, or the like; and R
3
and R
4
represent —CO—R
5
or the like.
C12 Modified erythromycin macrolides and ketolides having antibacterial activity
申请人:——
公开号:US20030125266A1
公开(公告)日:2003-07-03
Antimicrobial macrolide compounds are provided having formulas II:
1
as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.
Antimicrobial macrolide and ketolide compounds are provided having formulas XII:
as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.